Resources

Fundraising, collaboration, IP and leadership in focus as founders and investors shared practical advice for scaling in the UK

King’s College London has spun out Korecyte Bio Ltd (Korecyte) and Cell and Gene Therapy Catapult (CGT Catapult) has enabled the spinout.

Chris Molloy discusses Government engagement, the King’s Speech, health data, Isomorphic’s huge raise, the Start-up Festival and expanding BIA’s reach

BIA CEO Chris Molloy discusses the vision for data report, rare disease R&D, Women in Biotech, Europe GMO rules, Bio€quity and Swiss Biotech Day

The project will focus on advancing MDX-201, an innovative ADC that links a cytotoxic payload with a first-in-class monoclonal antibody (MDX-124) that targets annexin-A1.

Stevenage Bioscience Catalyst is deeply saddened to share the news that our CEO, Dr Sally Ann Forsyth OBE, passed away at home on Saturday 2 May after a long battle with illness.

CellCentric announces oversubscribed $220 Million Series D financing to advance pivotal trials of Inobrodib in Multiple Myeloma

In this guest blog, Catherine Hsu Steve Cardosi discuss Convertible Loan Notes (CLNs).

Cytospire Therapeutics announces the closing of an oversubscribed £61 million ($83 million) Series A financing.

In this guest blog, Asma Aslam says that rising domestic costs and strong overseas capabilities are pushing companies to subcontract abroad.

Stratosvir has received support from Cell and Gene Therapy Catapult (CGT Catapult), including investment from the Cross Catapult Investment Pilot.

It has been an extremely challenging time for biotech post COVID-19 boom, but our Q1 financing report offers hope with continued positive momentum.

UK biotech financing showed signs of recovery in the first quarter of 2026, driven by a rebound in venture capital investment.

In this blog, Ethan Almond reflects on the inaugral BioSolutions UK conference, which brought together over 200 innovators, policymakers and industry leaders alongside an additional 29 investors.

In this guest blog, Lee Smith and Spiros Servos argue that early-stage biotech leaders who secure investment in 2026 are those who integrate commercial thinking early, aligning science, clinical strategy and market realities into a credible narrative for investors.

Back from our Easter break, we’re hitting the ground running with an update on the publication of agreed text underpinning the UK-US pharmaceuticals agreement.

Lewis Miles discusses changes to EMIs, EISs and VCTs coming into force.

Fermtech has raised £2.5m to scale Koji Cocoa™, a fermentation-based cocoa ingredient made from cocoa shells that delivers 25–33% cost savings and up to 98% lower carbon emissions.